Comparison of β-blocker agents and mortality in maintenance hemodialysis patients: an international cohort study
Clinical Kidney Journal · 01.05.2024 · 17 (5)
DOI: 10.1093/ckj/sfae087 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Kidney Journal, online erschienen am 27.03.2024. Verfasst von Corey Toye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, University of Ottawa, Ottawa, ON, Canada. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes.
Abstract (Originalsprache)
Background
Despite a lack of clinical trial data, β-blockers are widely prescribed to dialysis patients. Whether specific β-blocker agents are associated with improved long-term outcomes compared with alternative β-blocker agents in the dialysis population remains uncertain.
Methods
We analyzed data from an international cohort study of 10 125 patients on maintenance hemodialysis across 18 countries that were newly prescribed a β-blocker medication within the Dialysis Outcomes and Practice Patterns Study (DOPPS). The following β-blocker agents were compared: metoprolol, atenolol, bisoprolol and carvedilol. Multivariable Cox proportional hazards models were used to estimate the association between the newly prescribed β-blocker agent and all-cause mortality. Stratified analyses were performed on patients with and without a prior history of cardiovascular disease.
Results
The mean (standard deviation) age in the cohort was 63 (15) years and 57% of participants were male. The most commonly prescribed β-blocker agent was metoprolol (49%), followed by carvedilol (29%), atenolol (11%) and bisoprolol (11%). Compared with metoprolol, atenolol {adjusted hazard ratio (HR) 0.77 [95% confidence interval (CI) 0.65–0.90]} was associated with a lower mortality risk. There was no difference in mortality risk with bisoprolol [adjusted HR 0.99 (95% CI 0.82–1.20)] or carvedilol [adjusted HR 0.95 (95% CI 0.82–1.09)] compared with metoprolol. These results were consistent upon stratification of patients by presence or absence of a prior history of cardiovascular disease.
Conclusions
Among patients on maintenance hemodialysis who were newly prescribed β-blocker medications, atenolol was associated with the lowest mortality risk compared with alternative agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology, University of Ottawa, Ottawa, ON, Canada.
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
- Arbor Research Collaborative for Health, Ann Arbor, MI, USA.
ORCID-Profile: Gregory L Hundemer
Förderung
- Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes
Zitieren
APA
Toye, C., Sood, M. M., Mallick, R., Akbari, A., Bieber, B., Karaboyas, A., Guedes, M., & Hundemer, G. L. (2024). Comparison of β-blocker agents and mortality in maintenance hemodialysis patients: an international cohort study. Clinical Kidney Journal, 17(5). https://doi.org/10.1093/ckj/sfae087
Vancouver
Toye C, Sood MM, Mallick R, Akbari A, Bieber B, Karaboyas A, et al. Comparison of β-blocker agents and mortality in maintenance hemodialysis patients: an international cohort study. Clinical Kidney Journal. 2024;17(5). doi:10.1093/ckj/sfae087
BibTeX
@article{Toye2024,
author = {Toye, Corey and Sood, Manish M and Mallick, Ranjeeta and Akbari, Ayub and Bieber, Brian and Karaboyas, Angelo and Guedes, Murilo and Hundemer, Gregory L},
title = {Comparison of β-blocker agents and mortality in maintenance hemodialysis patients: an international cohort study},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {5},
doi = {10.1093/ckj/sfae087}
}
EUVIMED